Reactive Thrombocytosis Associated with Acute Myocardial Infarction following STEMI with Percutaneous Coronary Intervention

Nat Dumrongmongcolgul; Charoen Mankongpaisarnrung; Grerk Sutamtewagul; Nattamol Hosiriluck; Timothy Chen; Alexander Trujillo; Nicholas Dcunha; Kenneth Nugent; Leigh Ann Jenkins

doi:10.1155/2013/707438

Back

Reactive Thrombocytosis Associated with Acute Myocardial Infarction following STEMI with Percutaneous Coronary Intervention

Journal article

Open access

Peer reviewed

Reactive Thrombocytosis Associated with Acute Myocardial Infarction following STEMI with Percutaneous Coronary Intervention

Nat Dumrongmongcolgul, Charoen Mankongpaisarnrung, Grerk Sutamtewagul, Nattamol Hosiriluck, Timothy Chen, Alexander Trujillo, Nicholas Dcunha, Kenneth Nugent and Leigh Ann Jenkins

Case reports in cardiology, Vol.2013, pp.1-3

2013

DOI: 10.1155/2013/707438

PMCID: PMC4008175

PMID: 24829806

Files and links (1)

url

https://doi.org/10.1155/2013/707438View

Published (Version of record) Open Access

Abstract

The etiology of thrombocytosis can be classified into reactive and essential forms. The rate of thromboembolic events is higher in essential thrombocytosis, and these events include strokes, transient ischemic attacks, retinal artery or retinal vein occlusions, digital ischemia, and acute coronary syndrome. In a study of 732 medical and surgical patients with thrombocytosis, 88% had reactive thrombocytosis. Patients with reactive thrombocytosis do not require cytoreductive medications or antiplatelet treatment. We report a healthy 40-year-old man without any medical problems who developed a new episode of myocardial infarction associated with thrombocytosis after an episode of myocardial infarction followed by percutaneous coronary intervention. He had thrombocytosis, and his platelet function test did not reveal adequate inhibition. To treat his acute coronary syndrome, therapeutic enoxaparin was added, and clopidrogel was substituted with ticagrelor. We decided to start hydroxyurea to reduce platelets counts. Enoxaparin and hydroxyurea were discontinued when platelet count returned to baseline. JAK-2 and BCR/ABL mutations were negative. This case report highlights a clinical dilemma (reactive thrombocytosis), which is challenging in terms of management and pathophysiology.

Details

Title: Subtitle: Reactive Thrombocytosis Associated with Acute Myocardial Infarction following STEMI with Percutaneous Coronary Intervention
Creators: Nat Dumrongmongcolgul - Texas Tech University Health Sciences Center
Charoen Mankongpaisarnrung - Texas Tech University Health Sciences Center
Grerk Sutamtewagul - Texas Tech University Health Sciences Center
Nattamol Hosiriluck - Texas Tech University Health Sciences Center
Timothy Chen - Texas Tech University Health Sciences Center
Alexander Trujillo - Texas Tech University Health Sciences Center
Nicholas Dcunha - Department of Internal Medicine, Texas Tech University Health Sciences Center, 3601 4th Street, Indiana Avenue, Lubbock, TX 79430, USA
Kenneth Nugent - Texas Tech University Health Sciences Center
Leigh Ann Jenkins - Texas Tech University Health Sciences Center
Resource Type: Journal article
Publication Details: Case reports in cardiology, Vol.2013, pp.1-3
DOI: 10.1155/2013/707438
PMID: 24829806
PMCID: PMC4008175
NLM abbreviation: Case Rep Cardiol
ISSN: 2090-6404
eISSN: 2090-6412
Language: English
Date published: 2013
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984363285202771

Metrics

89 Record Views

9 Times Cited - Web of Science